The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its legacy within the broader sector now raises questions about future returns . Copycat versions are undercutting patent protection , causing worries that betting on companies heavily reliant to Viagra's once-dominant position could be a dangerou